Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Has Average Price Target of $22.59

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been given a consensus recommendation of “Reduce” by the twenty-one research firms that are covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $22.59.

Several research firms have recently weighed in on SRPT. William Blair upgraded shares of Sarepta Therapeutics to a “hold” rating in a research report on Wednesday, September 23rd. Weiss Ratings upgraded shares of Sarepta Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. JPMorgan Chase & Co. dropped their target price on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, September 30th. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a research report on Monday, September 28th. Finally, Benchmark reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 9th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at about $341,339,000. First Trust Advisors LP increased its holdings in Sarepta Therapeutics by 107.6% in the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock worth $89,995,000 after purchasing an additional 2,143,211 shares in the last quarter. Bank of America Corp DE bought a new stake in Sarepta Therapeutics in the second quarter worth approximately $36,946,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Sarepta Therapeutics in the second quarter worth approximately $17,494,000. Finally, Legal & General Group Plc bought a new stake in Sarepta Therapeutics in the second quarter worth approximately $15,771,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $17.79 on Tuesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. Sarepta Therapeutics has a fifty-two week low of $14.68 and a fifty-two week high of $24.68. The company has a 50 day simple moving average of $19.29 and a two-hundred day simple moving average of $18.73. The company has a market capitalization of $1.88 billion, a PE ratio of -6.13, a P/E/G ratio of 0.31 and a beta of 0.38.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. During the same quarter in the previous year, the company earned $2.02 EPS. The company’s revenue for the quarter was down 34.3% on a year-over-year basis. Research analysts anticipate that Sarepta Therapeutics will post 3.27 earnings per share for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.